App-Quantinova.ai

A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.

Jayesh Desai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tislelizumab

Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients.

Guillermo de Velasco - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?

Thierry Landre - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nivolumab

Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone.

Michael Andrew Postow - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ipilimumab

Patient-derived tumor xenografts in humanized NSG-SGM3 mice: a new immuno-oncology platform.

Li-Chin Yao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Immune cell activation among lung adenocarcinoma and squamous cell carcinoma intrinsic subtypes and CD274 (PD-L1) expression.

Hawazin Faruki - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.

Omid Hamid - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

AGI-134, a fully synthetic -Gal-based cancer immunotherapy: Synergy with an anti-PD-1 antibody and pre-clinical pharmacokinetic and toxicity profiles.

Sascha A. Kristian - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.

Chrisann Kyi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Poly-ICLC

Adjuvant cancer peptide vaccine for pathological node positive esophageal SCC patients who underwent preoperative therapy followed by R0 resection.

Takushi Yasuda - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Peptide vaccine

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.

Garth S Herbert - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effect of cancer vaccine formulation on synergy with anti-CTLA-4 and anti-PD-L1 checkpoint blockade therapy of cancer.

Yared Hailemichael - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

CVac

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

Johanna C. Bendell - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Atezolizumab

NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).

Van Karlyle Morris - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nivolumab

CREST: Randomised phase III study of stenting as a bridge to surgery in obstructing colorectal cancer-Results of the UK ColoRectal Endoscopic Stenting Trial (CREST).

James Hill - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

stannous fluoride

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized StudyProdige 14 accord 21 (METHEP-2), a unicancer GI trial.

Marc Ychou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Bevacizumab

Final results of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.

Carlo Aschele - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

Oxaliplatin

Phase II trials of cetuximab plus combined modality therapy (CMT) in squamous cell carcinoma of the anal canal (SCCAC) with and without human immunodeficiency virus (HIV) infection.

Madhur Garg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Erbitux

Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients.

Albert Abad - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Bevacizumab

Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials.

Thomas Aparicio - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts